Bellevue Group AG — 13F Holdings & Portfolio
CIK 1674546 · latest 13F-HR filed 2026-08-14
Bellevue Group AG manages $4.75B in 13F-reported U.S. long-equity assets across 164 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are AMGN (6.34%), ARGX (5.88%), VRTX (5.83%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 17 new positions and exited 24; 70 existing positions rose in reported value and 48 fell.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
Long-equity book
Distinct positions
Filed 2026-08-14
vs 2026-03-31
Portfolio charts
Latest quarter's book, what changed, and how the portfolio has evolved across filings.
Portfolio map
Q2 26Box size = position value; colour = change in share count vs the prior quarter (green added, red trimmed, blue new). Rows split across managers or share classes are combined. Click a box for the stock.
Sector mix
% of 13F valueSectors from each company's SIC code; funds and ETFs grouped separately.
Biggest buys and sells
Q1 26 → Q2 26Estimated from the change in shares held × the quarter-end price, so price moves alone don't count as buying. New and exited positions are included.
13F assets and positions
4 quartersTotal reported 13F value (bars) and number of positions (line) each quarter. Value changes include market moves.
Top positions over time
reported valueThe eight largest current positions, valued at each quarter end.
Concentration
top 10 = 42.9%Cumulative share of the portfolio held in the largest N positions.
| Name | Title / Status | Ownership | Type |
|---|
Quarter-over-quarter changes
Changes in reported position value vs the prior 13F, so price moves count too, not just shares bought or sold.
Top Adds (vs prior quarter)
- AMGEN INC$204.4M +196.7%
- INSMED INC$146.9M +8954.7%
- ORUKA THERAPEUTICS INC$132.8M +534.2%
- GILEAD SCIENCES INC$109.7M +67.3%
- UNITED THERAPEUTICS CORP DEL$100.9M +8193.4%
Top Trims
- REGENERON PHARMACEUTICALS-$117.2M -54.4%
- KRYSTAL BIOTECH INC-$95.6M -76.8%
- ALNYLAM PHARMACEUTICALS INC-$77.3M -99.6%
- IONIS PHARMACEUTICALS INC-$59.5M -43.5%
- BOSTON SCIENTIFIC CORP-$54.2M -58.8%
New Positions
- AVALYN PHARMACEUTICALS INC$44.4M
- CG ONCOLOGY INC$35.1M
- SEAPORT THERAPEUTICS INC$23.9M
- PALVELLA THERAPEUTICS INC NE$23.7M
- SPYRE THERAPEUTICS INC$20.4M
Exited Positions
- EDGEWISE THERAPEUTICS INC$48.1M
- INSPIRE MED SYS INC$5.1M
- PENUMBRA INC$4.0M
- ATRIUM THERAPEUTICS INC$3.5M
- MASIMO CORP$1.6M
Bellevue Group AG Holdings (2026-06-30)
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | AMGEN INC | AMGN | 031162100 | $301.1M | 6.34% | 831,588 | SH |
| 2 | ARGENX SE | ARGX | 04016X101 | $279.3M | 5.88% | 301,000 | SH |
| 3 | VERTEX PHARMACEUTICALS INC | VRTX | 92532F100 | $276.9M | 5.83% | 557,375 | SH |
| 4 | GILEAD SCIENCES INC | GILD | 375558103 | $264.4M | 5.56% | 2,093,000 | SH |
| 5 | REVOLUTION MEDICINES INC | RVMD | 76155X100 | $195.2M | 4.11% | 1,042,424 | SH |
| 6 | ORUKA THERAPEUTICS INC | ORKA | 687604108 | $157.7M | 3.32% | 1,657,190 | SH |
| 7 | INSMED INC | INSM | 457669307 | $147.3M | 3.10% | 1,381,740 | SH |
| 8 | SCHOLAR ROCK HLDG CORP | SRRK | 80706P103 | $134.5M | 2.83% | 2,445,032 | SH |
| 9 | NUVALENT INC | NUVL | 670703107 | $130.1M | 2.74% | 1,053,268 | SH |
| 10 | VIRIDIAN THERAPEUTICS INC | VRDN | 92790C104 | $123.4M | 2.60% | 6,717,515 | SH |
| 11 | RELAY THERAPEUTICS INC | RLAY | 75943R102 | $115.7M | 2.43% | 6,184,046 | SH |
| 12 | VAXCYTE INC | PCVX | 92243G108 | $114.4M | 2.41% | 1,967,377 | SH |
| 13 | INTUITIVE SURGICAL INC | ISRG | 46120E602 | $101.3M | 2.13% | 254,809 | SH |
| 14 | UNITED THERAPEUTICS CORP DEL | UTHR | 91307C102 | $98.8M | 2.08% | 182,301 | SH |
| 15 | CRINETICS PHARMACEUTICALS IN | CRNX | 22663K107 | $98.0M | 2.06% | 2,620,000 | SH |
| 16 | REGENERON PHARMACEUTICALS | REGN | 75886F107 | $97.9M | 2.06% | 157,000 | SH |
| 17 | IMMUNOCORE HLDGS PLC | IMCR | 45258D105 | $88.5M | 1.86% | 2,788,245 | SH |
| 18 | BRIDGEBIO PHARMA INC | BBIO | 10806X102 | $87.2M | 1.83% | 1,170,130 | SH |
| 19 | ABBOTT LABORATORIES | ABT | 002824100 | $85.9M | 1.81% | 947,115 | SH |
| 20 | STRYKER CORPORATION | SYK | 863667101 | $84.5M | 1.78% | 268,461 | SH |
| 21 | MEDTRONIC PLC | MDT | G5960L103 | $77.8M | 1.64% | 994,233 | SH |
| 22 | ENLIVEN THERAPEUTICS INC | ELVN | 29337E102 | $75.6M | 1.59% | 1,490,000 | SH |
| 23 | IONIS PHARMACEUTICALS INC | IONS | 462222100 | $74.9M | 1.58% | 944,577 | SH |
| 24 | VERA THERAPEUTICS INC | VERA | 92337R101 | $72.6M | 1.53% | 1,692,906 | SH |
| 25 | JADE BIOSCIENCES INC | JBIO | 008064206 | $67.9M | 1.43% | 3,057,996 | SH |
| 26 | EDWARDS LIFESCIENCES CORP | EW | 28176E108 | $66.9M | 1.41% | 739,234 | SH |
| 27 | ULTRAGENYX PHARMACEUTICAL IN | RARE | 90400D108 | $66.2M | 1.39% | 1,982,775 | SH |
| 28 | UNITEDHEALTH GROUP INC | UNH | 91324P102 | $62.0M | 1.30% | 149,127 | SH |
| 29 | DEXCOM INC | DXCM | 252131107 | $55.4M | 1.17% | 822,489 | SH |
| 30 | CELLDEX THERAPEUTICS INC NEW | CLDX | 15117B202 | $44.7M | 0.94% | 1,200,000 | SH |
| 31 | AVALYN PHARMACEUTICALS INC | AVLN | 05348Y105 | $44.4M | 0.94% | 1,350,000 | SH |
| 32 | DAMORA THERAPEUTICS INC | DMRA | 36322Q206 | $42.1M | 0.89% | 1,618,846 | SH |
| 33 | DISC MEDICINE INC | IRON | 254604101 | $41.0M | 0.86% | 560,000 | SH |
| 34 | THERMO FISHER SCIENTIFIC INC | TMO | 883556102 | $40.0M | 0.84% | 79,816 | SH |
| 35 | BOSTON SCIENTIFIC CORP | BSX | 101137107 | $37.9M | 0.80% | 887,650 | SH |
| 36 | ELI LILLY & CO | LLY | 532457108 | $35.8M | 0.75% | 29,882 | SH |
| 37 | CG ONCOLOGY INC | CGON | 156944100 | $35.1M | 0.74% | 493,596 | SH |
| 38 | IDEXX LABS INC | IDXX | 45168D104 | $32.5M | 0.68% | 61,780 | SH |
| 39 | RESMED INC | RMD | 761152107 | $28.9M | 0.61% | 148,195 | SH |
| 40 | MONTE ROSA THERAPEUTICS INC | GLUE | 61225M102 | $28.8M | 0.61% | 1,190,000 | SH |
| 41 | KRYSTAL BIOTECH INC | KRYS | 501147102 | $28.2M | 0.59% | 76,000 | SH |
| 42 | DANAHER CORP DEL | DHR | 235851102 | $27.4M | 0.58% | 143,844 | SH |
| 43 | JOHNSON & JOHNSON | JNJ | 478160104 | $26.2M | 0.55% | 103,280 | SH |
| 44 | SEAPORT THERAPEUTICS INC | SPTX | 81221K108 | $23.9M | 0.50% | 1,100,000 | SH |
| 45 | PALVELLA THERAPEUTICS INC NE | PVLA | 697947109 | $23.7M | 0.50% | 155,000 | SH |
| 46 | ALIGN TECHNOLOGY INC | ALGN | 016255101 | $23.6M | 0.50% | 139,680 | SH |
| 47 | ANNEXON INC | ANNX | 03589W102 | $23.4M | 0.49% | 4,100,016 | SH |
| 48 | HUMANA INC | HUM | 444859102 | $23.2M | 0.49% | 58,398 | SH |
| 49 | ELEVANCE HEALTH INC FORMERLY | ELV | 036752103 | $21.8M | 0.46% | 56,449 | SH |
| 50 | TANGO THERAPEUTICS INC | TNGX | 87583X109 | $21.7M | 0.46% | 694,182 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-06-30 | 2026-08-14 | $4.75B | 164 | 0001104659-26-096739 |
| 2026-03-31 | 2026-05-15 | $4.20B | 167 | 0001104659-26-061375 |
| 2025-12-31 | 2026-02-17 | $5.28B | 213 | 0001104659-26-016360 |
| 2025-09-30 | 2025-11-14 | $4.81B | 186 | 0001104659-25-112697 |
ZURICH CH-8001